Welcome to HCV Advocate’s hepatitis blog. The intent of this blog is to keep our website audience up-to-date on information about hepatitis and to answer some of our web site and training audience questions. People are encouraged to submit questions and post comments.

For more information on how to use this blog, the HCV drug pipeline, and for more information on HCV clinical trials click here

Be sure to check out our other blogs: The HBV Advocate Blog and Hepatitis & Tattoos.


Alan Franciscus

Editor-in-Chief

HCV Advocate


Showing posts with label therapeutic vaccine. Show all posts
Showing posts with label therapeutic vaccine. Show all posts

Thursday, August 27, 2015

Cambridge biotech gets funding for development of hepatitis C vaccine

As several biotechs focus on developing lucrative hepatitis C drugs, a Cambridge firm has received funding to help develop a hepatitis C vaccine.

VBI Vaccines (Nasdaq: VBIV) has secured $6.29 million from a variety of venture capital investors, including new investor RTW Investments, with participation from ARCH Venture Partners and Perceptive Advisors.

Under the terms, VBI sold 3 million shares of stock at approximately $2 a share, resulting in the raise.

Read more....
Posted by at No comments:
Labels: ,
Subscribe to: Posts (Atom)